# De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Source: https://onco.cc/trials/nct05255302/  
OnCo record `nct05255302` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of pemetrexed in lung cancer, run by Intergroupe Francophone de Cancerologie Thoracique, now recruiting.

## Summary

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction is a phase 2/3, randomised interventional study registered as NCT05255302 by Intergroupe Francophone de Cancerologie Thoracique, with a registry enrolment figure of 1360 participants, started 2022-05-02 and due to reach its primary completion in 2025-05. Interventions recorded: Pembrolizumab before randomization; Chemotherapy; Pemetrexed; Pembrolizumab after randomization. Conditions listed: Metastatic NSCLC. Primary outcome: Phase II: 18-month overall survival (OS); Phase III: overall survival. Lung eligibility wording from the registry: "Patients with histologically confirmed metastatic NSCLC (Stage IV accordingly to 8th classification TNM, UICC 2015)". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: DIAL
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05255302
- Phase: 2/3
- Setting: A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- Enrolled: 1360

## Sources

- ClinicalTrials.gov NCT05255302: https://clinicaltrials.gov/study/NCT05255302

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05255302.json